Drug Database
Back to search

Poland· PL-100477718

Zarixa

A rivaroxaban product containing rivaroxabanum, registered in Poland by Celon Pharma S.A.. The same ATC class is registered in 15 of our 19 countries.

ATC B01AF01

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedZarixaATCB01AF01REGISTER NO.PL-100477718PACKS LISTED5CHECKEDSeptember 27, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about rivaroxabanumAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Rivaroxaban is registered in 15 of 19 countries.

Countries holding a registration under ATC B01AF01 (rivaroxaban), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 9 of them publish a price we can compare per daily dose
Search rivaroxaban products by name

Rivaroxaban · ATC B01AF01

15 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Germany
  • Icelandprice
  • Ireland
  • Italyprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of rivaroxaban costs, country by country.

Normalised to the WHO defined daily dose (20 mg), the median price runs from $0.67 in France to $5.20 in United States — a ×7.7 gap.

  • 4 markets with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
  • US figures are pharmacy acquisition cost (CMS NADAC), not retail
Open the full comparison — free accountDrug prices for market access

Rivaroxaban · price per daily dose (20 mg)

USD · FX 28 Sept 2026

  • US United States$5.20 (acquisition cost)
  • CH Switzerland$2.66
  • IT Italy$1.08
  • FR France$0.67
Median listed price per WHO defined daily dose, in each market that publishes a price. US = pharmacy acquisition cost (CMS NADAC), not a retail price. Open the full comparison

The record

At a glance

URPL (Poland)
Active substance
Rivaroxabanum
Manufacturer
Celon Pharma S.A.
Country
Poland (PL)
ATC code
B01AF01
ATC class
Rivaroxaban
Defined daily dose
20 mg, O
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 5

2 priced
  • gtin
    05909991528546
    14 szt.
    PLN 37.02
  • gtin
    05909991528584
    28 szt.
    PLN 53.33
  • gtin
    05909991528577
  • gtin
    05909991528553
  • gtin
    05909991528560

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

391 interactions on record for rivaroxaban.

Graded by severity as the source publishes them — 134 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check rivaroxaban against other medicinesHow interaction checks work

Rivaroxaban · interactions on record

391 records

  • 134 severe
  • 213 moderate
  • 2 minor

Most severe, free to view

  • LonafarnibA16AX20severe
  • DicoumarolB01AA01severe
  • WarfarinB01AA03severe
  • HeparinB01AB01severe

42 more interactions with mechanism and management, from a commercially licensed source.

Sign in to check
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same class

Other records under B01AF01

Rivaroxaban, as other registers publish it.

All rivaroxaban products

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/ec49c5e9-03f9-42f5-aacd-b9ac5038e0fa
GET /v1/drugs/ec49c5e9-03f9-42f5-aacd-b9ac5038e0fa?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Kapsułki twarde",
  "source": "urpl",
  "strength": "15 mg",
  "packaging": "05909991528553 ¦ Rp ¦ 152535\n42 kaps.\n05909991528546 ¦ Rp ¦ 152536\n14 kaps.\n05909991528584 ¦ Rp ¦ 152537\n28 kaps.\n05909991528560 ¦ Rp ¦ 152538\n28 kaps.\n05909991528577 ¦ Rp ¦ 152539\n14 kaps.",
  "substance": "Rivaroxabanum 15 mg",
  "common_name": "Rivaroxabanum",
  "pl_product_id": "100477718",
  "pozwolenie_nr": "28166",
  "auth_procedure": "NAR",
  "authorisation_validity": "2028-12-21"
}
API referenceMCP serverPlans

See everything about rivaroxaban.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console